METHOD OF CORNEOCONJUNCTIVAL XEROSIS TREATMENT Russian patent published in 2018 - IPC A61F9/00 A61K31/185 A61K31/573 A61K31/715 A61K31/726 A61K31/728 A61P27/02 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology and clinical pharmacology, and can be used to treat corneoconjunctival xerosis. Method comprises administering in the form of eye drops of medicinal substances in a certain mode. 1 drop of drug, containing active ingredients tobramycin and dexamethasone, administered in patient conjunctival eye bag 4 times a day for 24 days. Drug, containing the active substances dextran-70 and hypromelase, administered for 30 days. In the first 24 days, 1 drop 4–6 times a day and 1 drop 3 times a day in the last 6 days. On the 20th day after the beginning of treatment, the drug containing the active substance parahaminobenzoic acid is administered, 1 drop 2 times a day for 10 days. On the 25th day after the start of treatment, a drug containing active ingredients sodium hyaluronate and succinic acid administered 1–2 drops 2 times a day for 14 days and the preparation containing sodium hyaluronate, B-panthenol and sodium chondroitin sulfate 1–2 drops once a day for 14 days. In this case, the administration of the drugs is carried out 30 minutes after the administration of the preparation containing sodium hyaluronate, B-panthenol and sodium chondroitin sulfate. Time of administration between other drugs is from above 15–20 minutes.

EFFECT: method stimulates the restoration of the structure of the epithelium of the conjunctiva and meibomian glands, which contributes to increased tear production, stability of the tear film, increases the thickness of the cornea and immunological resistance, does not lead to the thinning of the xerotically altered cornea.

3 cl, 4 ex, 2 tbl